Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Edmund Dunn reported proposed sales of Common Stock on Form 144 for GLUE. The filing lists multiple transactions, including 26,117 shares reported on 04/08/2026 for $450,622.72 and 25,164 shares reported on 02/27/2026 for $455,506.15. The excerpt also shows several stock option exercises dated 04/10/2026 with individual exercise quantities of 1,113; 13,350; 1,112; and 1,112 shares.
Monte Rosa Therapeutics’ Chief Business & Legal Officer, Nickson Philip, sold 5,845 shares of common stock in an open-market transaction. The sale on April 9, 2026 was executed at a weighted average price of $17.6925 per share, based on multiple trades within a narrow range. After this sale, he directly holds 55,000 shares of Monte Rosa Therapeutics common stock.
Edmund Dunn reported sales of Common Stock under Form 144. The filing lists 26,117 shares to be sold with a stock option exercise noted on 04/08/2026 and cash as the payment method. The filing also lists past sales of 25,164 shares (02/27/2026), 536 shares (03/02/2026), and 139 shares (03/04/2026) with the dollar amounts shown.
Monte Rosa Therapeutics, Inc. Principal Accounting Officer Matthew Bowen received new equity awards. He was granted a stock option covering 19,500 shares of common stock at an exercise price of $16.93 per share, expiring on April 5, 2036. Separately, he received 4,300 restricted stock units, each representing one share upon vesting. The RSUs vest 25% on April 6, 2027, with the remainder in three equal annual installments, while the option vests 25% on April 6, 2027 and then in 36 substantially equal monthly installments, in each case subject to continued service. Following the RSU grant, he directly owns 25,904 shares of common stock.
Monte Rosa Therapeutics, Inc. executive Matthew Bowen, Principal Accounting Officer, filed an initial ownership report showing direct holdings of common stock and multiple stock option awards. He reports 21,604 shares of common stock held directly, which includes 3,590 unvested restricted stock units that convert into shares as they vest.
Bowen also holds several stock options to buy common stock at exercise prices ranging from $5.71 to $23.99 per share, with expiration dates between 2031 and 2036. These options vest over time, often with 25% vesting on a stated date and the balance in 36 monthly installments, contingent on continued service.
New Enterprise Associates 17 and affiliates filed Amendment No. 3 to their Schedule 13D on Monte Rosa Therapeutics. They report beneficial ownership of 7,692,298 shares of common stock, representing 9.6% of the company based on 80,015,667 shares outstanding as of March 2, 2026.
The amendment states their ownership percentage has fallen by more than 1% solely because the number of Monte Rosa shares outstanding increased, and that no reporting person has traded in the last 60 days. NEA 17 holds the shares for investment purposes and the group outlines no current plans to change control, influence major corporate actions, or alter the issuer’s capital structure. Ali Behbahani also holds options to purchase 104,732 shares, bringing his calculated beneficial stake to 7,797,030 shares, or 9.7%.
Monte Rosa Therapeutics provides an in-depth overview of its business, risks, and drug pipeline focused on molecular glue degraders, or MGDs, in this annual report. The company remains pre-revenue from drug sales and highlights a history of significant operating losses with expectations of continued losses.
Monte Rosa is advancing three core clinical programs: MRT-6160 for immune-mediated diseases (out-licensed to Novartis), MRT-8102 for NLRP3/IL-1/IL-6-driven inflammatory diseases, and MRT-2359 for MYC-driven cancers such as metastatic castration-resistant prostate cancer. Early clinical data show deep target degradation, strong pharmacodynamic effects, and generally favorable safety profiles.
The company has entered major collaborations with Novartis and Roche that include substantial upfront payments and large potential milestone and royalty streams. As of June 30, 2025, the aggregate market value of common equity held by non-affiliates was $212 million, and 80,015,667 shares of common stock were outstanding as of March 2, 2026.
Monte Rosa Therapeutics reported fourth quarter and full-year 2025 results alongside major clinical and financing milestones. Collaboration revenue was $2.8 million in Q4 2025 versus $60.6 million a year earlier, and $123.7 million for 2025 versus $75.6 million in 2024. Full-year net loss improved to $38.6 million from $72.7 million despite higher R&D spending of $141.5 million.
Cash, cash equivalents, restricted cash and marketable securities were $382.1 million as of December 31, 2025. A follow-on equity offering in January 2026 raised approximately $345 million gross (about $323.8 million net), extending the company’s funding runway into 2029.
Clinically, NEK7-directed MGD MRT-8102 showed strong Phase 1 anti-inflammatory activity with CRP reductions of 85% and favorable safety in 88 treated participants, supporting multiple planned Phase 2 trials starting in 2026–2027. Oncology candidate MRT-2359 delivered a 100% PSA response rate in AR-mutant mCRPC patients in combination with enzalutamide, with a Phase 2 study with apalutamide planned for Q3 2026. Partnered VAV1-directed MGD MRT-6160 is progressing toward Novartis-led Phase 2 studies, backed by a collaboration that could yield up to $2.1 billion in milestones.
Monte Rosa Therapeutics Principal Accounting Officer Edmund Dunn reported an automatic sale of 139 shares of common stock. The shares were sold on March 4, 2026 at a price of $17.96 per share to cover tax withholding obligations triggered by the vesting of restricted stock units. According to the disclosure, these sales were automatic and not at Dunn’s discretion. After this tax-related transaction, he beneficially owned 22,554 shares of Monte Rosa Therapeutics common stock directly.